MoonLake Immunotherapeutics (MLTX) Share-based Compensation (2021 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Share-based Compensation of $13.4 million for Q1 2026, up 378.64% quarter-over-quarter from -$4.8 million in Q4 2024.
MoonLake Immunotherapeutics (MLTX) Share-based Compensation (2021 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Share-based Compensation history runs 5 years deep, the most recent figure standing at $13.4 million for Q1 2026.
- In Q1 2026, Share-based Compensation changed N/A year-over-year to $13.4 million; the TTM figure through Mar 2026 stood at $13.4 million (up 1290.29% YoY), while the FY2024 annual figure was $555000.0, down 92.19% from the prior year.
- Share-based Compensation for Q1 2026 stood at $13.4 million, up from -$4.8 million in the prior quarter.
- The five-year high for Share-based Compensation was $13.4 million in Q1 2026, with the low at -$4.8 million in Q4 2024.
- The 4-year median for Share-based Compensation is $2.0 million (2022), against an average of $2.4 million.
- Peak annual rise in Share-based Compensation reached 249.17% in 2024, while the deepest fall reached 398.54% in 2024.
- MoonLake Immunotherapeutics' Share-based Compensation stood at $2.6 million in 2022, then slumped by 38.17% to $1.6 million in 2023, then plunged by 398.54% to -$4.8 million in 2024, then jumped by 378.64% to $13.4 million in 2026.
- Business Quant data shows MLTX's Share-based Compensation at $13.4 million in Q1 2026, -$4.8 million in Q4 2024, and $5.0 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - | 2.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.55 Mn |
| Jun 30, 2026 | 2.55 Mn |
| Mar 31, 2026 | 13.36 Mn |
| Mar 31, 2026 | 13.36 Mn |
| Dec 31, 2024 | -4.79 Mn |
| Dec 31, 2024 | -4.79 Mn |
| Sep 30, 2024 | 4.98 Mn |
| Sep 30, 2024 | 4.98 Mn |
| Jun 30, 2024 | -1.31 Mn |
| Jun 30, 2024 | -1.31 Mn |
| Mar 31, 2024 | 1.68 Mn |
| Mar 31, 2024 | 1.68 Mn |
| Dec 31, 2023 | 1.61 Mn |
| Dec 31, 2023 | 1.61 Mn |
| Sep 30, 2023 | 1.43 Mn |
| Sep 30, 2023 | 1.43 Mn |
| Jun 30, 2023 | 1.50 Mn |
| Jun 30, 2023 | 1.50 Mn |
| Mar 31, 2023 | 2.58 Mn |
| Mar 31, 2023 | 2.58 Mn |